PO.IM01.04 · 免疫学
利用放射诱导的表面蛋白靶点重编程肿瘤微环境
Leveraging radiation inducible surface protein targets for tumor microenvironment reprogramming
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
放射治疗(RT)是实体瘤患者最常见的治疗手段之一,超过50%的患者接受该治疗。然而,RT后肿瘤控制失败是一项重大的临床挑战。在本研究中,我们鉴定出一组新蛋白,作为多种癌症(包括乳腺癌和非小细胞肺癌)中的放射诱导表面蛋白。所表征的特定蛋白作为消耗代谢底物的酶发挥作用,从而改变肿瘤微环境(TME)以及细胞内在功能。我们使用细胞表面捕获质谱、bulk-RNA测序、荧光光谱和飞行时间质谱(CyTOF),全面表征了RT后我们的靶点上调,既作为表面蛋白,也表征了扰动的酶学后果。为增加表面表达的诱导,我们评估了RT与小分子及其他可溶性因子的组合策略。这些组合在体外显著增加了小鼠和人非小细胞肺癌细胞系中的表达。此外,在体内,肿瘤靶向的RT/联合治疗显著上调了肿瘤细胞上以及一部分巨噬细胞和成纤维细胞上我们关注的蛋白。功能研究提示这些巨噬细胞和成纤维细胞可能在TME内发挥免疫抑制作用。利用这些发现,我们开发了定向疗法,包括抗体-药物偶联物(ADCs)和抗原特异性嵌合抗原受体(CAR)T细胞,以清除靶点水平升高的肿瘤细胞和免疫抑制细胞,提供更有利于控制肿瘤的联合治疗。总之,我们已鉴定并表征了一个放射诱导的治疗靶点,为重编程TME和改善治疗疗效提供了框架。
查看英文原文 English abstract
Radiation Therapy (RT) is one of the most common treatments for patients with solid tumors, administered to over 50% of patients. Failure of tumor control following RT, however, is a significant clinical challenge. In the present study, we identify a suite of novel proteins as radiation-inducible surface proteins across a variety of cancers, including breast and non-small cell lung cancers. Specific proteins characterized act as enzymes which deplete metabolic substrates, thus altering both the tumor microenvironment (TME) as well as cell intrinsic function. Using cell-surface capture mass spectrometry, bulk-RNA sequencing, fluorescence spectrometry, and cytometry by time of flight (CyTOF), we comprehensively characterize our target upregulation following RT, both as a surface protein and the enzymatic consequence of perturbation. To increase induction of surface expression, we evaluated combinatorial strategies of RT with small molecules and other soluble factors. These combinations significantly increased expression in vitro in both mouse and human non-small cell lung cancer cell lines. Additionally, in vivo , tumor-targeted RT/combination treatment significantly upregulated our protein of interest on tumor cells, as well as on a subset of macrophages and fibroblasts. Functional investigation suggests these macrophages and fibroblasts may have an immunosuppressive role within the TME. Leveraging these findings, we developed directed therapies, including antibody-drug conjugates (ADCs) and antigen-specific chimeric antigen receptor (CAR) T cells, to ablate both tumor and immunosuppressive cells with increased levels of the target, providing a more conducive combinatorial therapy to control tumors. In conclusion, we have identified and characterized a radiation-inducible therapeutic target, providing framework for reprogramming the TME and improving treatment efficacy.
利益披露 Disclosure
C. M. Tamaki, None..
M. Foisey, None..
C. Chen, None..
N. Cho, None.